Ad is loading...
APHDX
Price
$20.90
Change
-$0.46 (-2.15%)
Updated
Nov 15 closing price
RSLDX
Price
$69.58
Change
-$0.86 (-1.22%)
Updated
Nov 15 closing price
Ad is loading...

APHDX vs RSLDX

Header iconAPHDX vs RSLDX Comparison
Open Charts APHDX vs RSLDXBanner chart's image
Artisan Global Discovery Institutional
Price$20.90
Change-$0.46 (-2.15%)
VolumeN/A
CapitalizationN/A
American Funds SMALLCAP World R5E
Price$69.58
Change-$0.86 (-1.22%)
VolumeN/A
CapitalizationN/A
APHDX vs RSLDX Comparison Chart
Loading...
View a ticker or compare two or three
VS
APHDX vs. RSLDX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APHDX is a StrongBuy and RSLDX is a Buy.

FUNDAMENTALS
Fundamentals
RSLDX has more cash in the bank: 74.7B vs. APHDX (238M). RSLDX pays higher dividends than APHDX: RSLDX (0.83) vs APHDX (0.00). APHDX was incepted earlier than RSLDX: APHDX (5 years) vs RSLDX (9 years). APHDX is a more actively managed with annual turnover of: 50.02 vs. RSLDX (29.00). RSLDX has a lower initial minimum investment than APHDX: RSLDX (250) vs APHDX (1000000). APHDX annual gain was more profitable for investors over the last year : 25.90 vs. RSLDX (16.23).
APHDXRSLDXAPHDX / RSLDX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence5 years9 years-
Gain YTD13.5873.928346%
Front LoadN/AN/A-
Min. Initial Investment1000000250400,000%
Min. Initial Investment IRAN/AN/A-
Net Assets238M74.7B0%
Annual Yield % from dividends0.000.83-
Returns for 1 year25.9016.23160%
Returns for 3 years-16.53-25.4265%
Returns for 5 yearsN/A20.19-
Returns for 10 yearsN/AN/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NSA43.130.80
+1.89%
National Storage Affiliates Trust
CISS1.110.02
+1.83%
C3is
UTI19.610.07
+0.36%
Universal Technical Institute
TXT84.91-1.19
-1.38%
Textron
HRTX1.19-0.05
-4.03%
Heron Therapeutics